EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract

Mohammad Jad Moussa iD, Georges C Tabet, Arlene O Siefker-Radtke, Lianchun Xiao, Nathaniel R Wilson, Jianjun Gao, Christopher J Logothetis, Petros Grivas, Byron Lee, Amishi Y Shah, Pavlos Msaouel, Roger Li und 8 weitere

Cancer Medicine · 2025-01 · 14 (2)

DOI: 10.1002/cam4.70594 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 20.01.2025. Verfasst von Mohammad Jad Moussa und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Carcinoma, Neuroendocrine, Carcinoma, Small Cell, Neoplasm Recurrence, Local, Urologic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ingram Family Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Small cell neuroendocrine carcinoma of the urinary tract (SCNEC‐URO) has an inferior prognosis compared to conventional urothelial carcinoma (UC). Here, we evaluate the predictors and patterns of relapse after surgery. Materials and Methods We identified a definitive‐surgery cohort ( n = 224) from an institutional database of patients with cT1‐T4NxM0 SCNEC‐URO treated in 1985–2021. Histopathologic review was conducted by independent pathologists. Relapse event was the time‐to‐event outcome, and relapse probabilities were estimated using a competing risk method with cumulative incidence functions (CIFs). Fine‐Gray distribution models assessed covariate associations.

Results

Most patients (161, 71.9%) received neoadjuvant chemotherapy (neoCTX). Ninety two (41%) patients had relapse with 77 (83.7%) having distant organs as first metastatic sites, including 10 (10.9%) with exclusive central nervous system (CNS) metastases, mostly (9/10) within 1 year of surgery. Patients with pathologic complete response (pCR) after neoCTx had the lowest 5‐year CIF (16.5% [95% CI 9.3%–25.6%]). Patients with remaining exclusively small cell (SC) histology had the highest CIF (85.7% [95% CI 46.6–96.9]). Patients with eradicated SCNEC but remaining UC components had an intermediate‐risk CIF (32.5% [95% CI 18.6–47.2]). Multivariable analysis adjusting for neoCTx, clinical stage at diagnosis (T3/4, N0/N+ vs. T1/T2, N0), and pathologic stage (pN+ vs. pN0) demonstrated that any SCNEC histology at resection (vs. pCR) was associated with relapse risk (hazard ratio = 3.69 [95% CI 1.91–7.13], p = 0.0001).

Conclusions

SCNEC‐URO is a systemic disease with high risk of distant relapse including CNS. Our findings highlight unmet needs for neoadjuvant/adjuvant approaches targeting the rare SCNEC subtype and suggest adding CNS surveillance within the first year after definitive surgery to high‐risk patients. Précis (Condensed Abstract) Alongside neoadjuvant chemotherapy and cancer stage, histology at resection strongly impacts relapse risk in small cell neuroendocrine carcinomas of the urinary tract. The incidence of brain metastasis is notably higher than in “traditional” urothelial cancer within the first year after surgery, especially if small cell cancer persists, thus necessitating close neurological monitoring during this period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, NeuroendocrineCarcinoma, Small CellNeoplasm Recurrence, LocalUrologic NeoplasmsHumansFemaleMaleMiddle AgedAgedDisease ProgressionPrognosisNeoadjuvant TherapyRetrospective StudiesAdultAged, 80 and over

Stichwörter der Autor:innen

bladder cancermetastatic relapseneuroendocrine carcinomaprognostic factorssmall cell carcinomasurgical outcomesurothelial carcinoma

Autor:innen und Institutionen

  • Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Pathology and Laboratory Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Division of Surgery, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Mohammad Jad Moussa, Omar Alhalabi

Förderung

  • Ingram Family Fund

Zitieren

APA

Moussa, M. J., Tabet, G. C., Siefker-Radtke, A. O., Xiao, L., Wilson, N. R., Gao, J., Logothetis, C. J., Grivas, P., Lee, B., Shah, A. Y., Msaouel, P., Li, R., Clemente, L. C., Zhao, J., Tannir, N. M., Kamat, A. M., Hansel, D. E., Guo, C. C., Campbell, M. T., & Alhalabi, O. (2025). Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract. Cancer Medicine, 14(2). https://doi.org/10.1002/cam4.70594

Vancouver

Moussa MJ, Tabet GC, Siefker-Radtke AO, Xiao L, Wilson NR, Gao J, et al. Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract. Cancer Medicine. 2025;14(2). doi:10.1002/cam4.70594

BibTeX
@article{Moussa2025,
  author = {Moussa, Mohammad Jad and Tabet, Georges C and Siefker-Radtke, Arlene O and Xiao, Lianchun and Wilson, Nathaniel R and Gao, Jianjun and Logothetis, Christopher J and Grivas, Petros and Lee, Byron and Shah, Amishi Y and Msaouel, Pavlos and Li, Roger and Clemente, Leticia Campos and Zhao, Jianping and Tannir, Nizar M and Kamat, Ashish M and Hansel, Donna E and Guo, Charles C and Campbell, Matthew T and Alhalabi, Omar},
  title = {Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {2},
  doi = {10.1002/cam4.70594}
}
Kostenlos starten →